Alfred Rudolph, M.D. Is Leaving as Chief Operating Officer
Monday November 20, 6:30 am ET
SAN MATEO, CA--(MARKET WIRE)--Nov 20, 2006 -- SciClone Pharmaceuticals (NASDAQ:SCLN - News) today announced that Alfred Rudolph, M.D., Chief Operating Officer, is leaving the Company, effective November 17, 2006. The Company is actively working to identify a successor. In the interim, Friedhelm Blobel, Ph.D., President and Chief Executive Officer, will assume the duties and functions of the position.
ADVERTISEMENT
Dr. Rudolph joined SciClone in 1997 to head the clinical, research, regulatory, manufacturing, and quality assurance functions of the Company. In 1998, he was appointed Chief Operating Officer. During his tenure in that office, SciClone expanded its registration approvals for the sale of its lead product ZADAXIN to dozens of countries, and conducted, by itself and with its European marketing partner Sigma-Tau, late stage clinical programs for ZADAXIN treatment of hepatitis C, malignant melanoma, and hepatocellular carcinoma.
"I am very positive about SciClone's prospects and current capabilities," stated Dr. Rudolph. "My years at SciClone, the organization we have built, and what we have achieved together have been professionally rewarding for me," he added.
"We are appreciative and thankful for Al's many contributions to SciClone," commented Dr. Blobel. "Al's guidance and leadership of his team members has been an important factor in the creation of the opportunities in SciClone's future." |
